Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders P Jørgensen

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
The Journal of Clinical Endocrinology and Metabolism|December 10, 2024
Extended-release Hydrocortisone Formulations-Is There a Clinically Meaningful Benefit?Sandra D Steintorsdottir, Marianne Øksnes, Anders P Jørgensen, et al.
Clinical Endocrinology|November 3, 2010
Interleukin 1 receptor antagonist is associated with changes in body composition during physiological GH substitution in patients with adult-onset growth hormone deficiencyThor Ueland, Anders P Jørgensen, Kristin Godang, et al.
European Journal of Endocrinology|March 25, 2006
Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiencyJens Bollerslev, Thor Ueland, Anders P Jørgensen, et al.
The Journal of Clinical Endocrinology and Metabolism|December 3, 2014
Increased serum and bone matrix levels of the secreted Wnt antagonist DKK-1 in patients with growth hormone deficiency in response to growth hormone treatmentThor Ueland, Nicoleta Cristina Olarescu, Anders P Jørgensen, et al.
Pituitary|April 11, 2025
Pasireotide as first line medical therapy for selected patients with acromegalyNicoleta C Olarescu, Anders P Jørgensen, Shahriar Atai, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2020
FSH Levels Are Related to E-cadherin Expression and Subcellular Location in Nonfunctioning Pituitary TumorsAnders J Kolnes, Kristin A B Øystese, Nicoleta C Olarescu, et al.
European Journal of Endocrinology|June 10, 2011
Increased serum and bone matrix levels of transforming growth factor {beta}1 in patients with GH deficiency in response to GH treatmentThor Ueland, Tove Lekva, Kari Otterdal, et al.
Scientific Reports|August 4, 2025
Immune cell subsets in autoimmune polyendocrine syndrome type IShahinul Islam, Bergithe E Oftedal, Miriam Gjerdevik, et al.
Cancers|January 5, 2021
TGFBR3L-An Uncharacterised Pituitary Specific Membrane Protein Detected in the Gonadotroph Cells in Non-Neoplastic and Tumour TissueEvelina Sjöstedt, Anders J Kolnes, Nicoleta C Olarescu, et al.
Iscience|April 18, 2024
Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1Thea Sjøgren, Shahinul Islam, Igor Filippov, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
The Journal of Clinical Endocrinology and Metabolism|December 10, 2024
Extended-release Hydrocortisone Formulations-Is There a Clinically Meaningful Benefit?Sandra D Steintorsdottir, Marianne Øksnes, Anders P Jørgensen, et al.
Clinical Endocrinology|November 3, 2010
Interleukin 1 receptor antagonist is associated with changes in body composition during physiological GH substitution in patients with adult-onset growth hormone deficiencyThor Ueland, Anders P Jørgensen, Kristin Godang, et al.
European Journal of Endocrinology|March 25, 2006
Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiencyJens Bollerslev, Thor Ueland, Anders P Jørgensen, et al.
The Journal of Clinical Endocrinology and Metabolism|December 3, 2014
Increased serum and bone matrix levels of the secreted Wnt antagonist DKK-1 in patients with growth hormone deficiency in response to growth hormone treatmentThor Ueland, Nicoleta Cristina Olarescu, Anders P Jørgensen, et al.
Pituitary|April 11, 2025
Pasireotide as first line medical therapy for selected patients with acromegalyNicoleta C Olarescu, Anders P Jørgensen, Shahriar Atai, et al.
The Journal of Clinical Endocrinology and Metabolism|May 19, 2020
FSH Levels Are Related to E-cadherin Expression and Subcellular Location in Nonfunctioning Pituitary TumorsAnders J Kolnes, Kristin A B Øystese, Nicoleta C Olarescu, et al.
European Journal of Endocrinology|June 10, 2011
Increased serum and bone matrix levels of transforming growth factor {beta}1 in patients with GH deficiency in response to GH treatmentThor Ueland, Tove Lekva, Kari Otterdal, et al.
Scientific Reports|August 4, 2025
Immune cell subsets in autoimmune polyendocrine syndrome type IShahinul Islam, Bergithe E Oftedal, Miriam Gjerdevik, et al.
Cancers|January 5, 2021
TGFBR3L-An Uncharacterised Pituitary Specific Membrane Protein Detected in the Gonadotroph Cells in Non-Neoplastic and Tumour TissueEvelina Sjöstedt, Anders J Kolnes, Nicoleta C Olarescu, et al.
Iscience|April 18, 2024
Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1Thea Sjøgren, Shahinul Islam, Igor Filippov, et al.
Pageof 2